Patrick Lin - Jan 31, 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Business - Strategy Off
Signature
/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Jan 31, 2024
Transactions value $
$9,525
Form type
4
Date filed
2/1/2024, 06:32 PM
Previous filing
Apr 12, 2024
Next filing
Aug 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $5.93K +2.5K +10.65% $2.37 26K Jan 31, 2024 Direct F1
transaction PCSA Common Stock Purchase $3.6K +1.5K +5.77% $2.40 27.5K Feb 1, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.